tiprankstipranks
Trending News
More News >
Disc Medicine, Inc. (IRON)
:IRON
US Market
Advertisement

Disc Medicine (IRON) Stock Forecast & Price Target

Compare
477 Followers
See the Price Targets and Ratings of:

IRON Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Disc
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IRON Stock 12 Month Forecast

Average Price Target

$99.25
▲(69.02% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $99.25 with a high forecast of $132.00 and a low forecast of $75.00. The average price target represents a 69.02% change from the last price of $58.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","133":"$133","64.75":"$64.8","87.5":"$87.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,64.75,87.5,110.25,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,64.58769230769231,70.20538461538462,75.82307692307693,81.44076923076923,87.05846153846154,92.67615384615385,98.29384615384615,103.91153846153847,109.52923076923076,115.14692307692309,120.76461538461538,126.38230769230769,{"y":132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,62.068461538461534,65.16692307692307,68.26538461538462,71.36384615384615,74.46230769230769,77.56076923076922,80.65923076923076,83.75769230769231,86.85615384615384,89.95461538461538,93.05307692307693,96.15153846153845,{"y":99.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,60.20307692307692,61.43615384615384,62.669230769230765,63.902307692307694,65.13538461538461,66.36846153846153,67.60153846153847,68.83461538461539,70.06769230769231,71.30076923076923,72.53384615384616,73.76692307692308,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$132.00Average Price Target$99.25Lowest Price Target$75.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on IRON
Cantor Fitzgerald
Cantor Fitzgerald
$132
Buy
124.80%
Upside
Reiterated
08/20/25
Cantor Fitzgerald Sticks to Its Buy Rating for Disc Medicine (IRON)Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $132.00 price target on Disc Medicine (NASDAQ: IRON).
Morgan Stanley Analyst forecast on IRON
Morgan Stanley
Morgan Stanley
$85$90
Buy
53.27%
Upside
Reiterated
08/18/25
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)
H.C. Wainwright Analyst forecast on IRON
H.C. Wainwright
H.C. Wainwright
$118
Buy
100.95%
Upside
Reiterated
08/08/25
H.C. Wainwright Reaffirms Their Buy Rating on Disc Medicine (IRON)
Truist Financial Analyst forecast on IRON
Truist Financial
Truist Financial
Buy
Reiterated
08/08/25
Disc Medicine (IRON) Receives a Buy from Truist Financial
Leerink Partners Analyst forecast on IRON
Leerink Partners
Leerink Partners
$85
Buy
44.75%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Quanterix (NASDAQ: QTRX) and PTC Therapeutics (NASDAQ: PTCT)We look forward to NDA submission for bitopertin in October 2025, as well as DISC-0974’s initial Phase 2 data in MF anemia (likely ASH in December) and additional Phase 1 results in Reason for report: EARNINGS $85.00 52-Week High – Low: $68.73 - $30.82 Shares Outstanding (mil): 35.2 Market Capitalization (mil): $2,006.0 $18.49 Dividend (ann): $0.00 0.0% Dec Yr 2024A 2025E (New) 2025E (Old) 2026E (New) 2026E (Old) Q1 0.0 0.0A -- -- -- Q2 0.0 0.0A -- -- -- Q3 0.0 0.0 -- -- -- Q4 0.0 0.0 -- -- -- FY Rev 0.0 0.0 -- $30.2 -- Q1 ($1.09) ($1.02)A -- -- -- ($1.20) -- -- Q3 ($0.89) ($1.43) -- -- -- ($1.70) -- -- FY EPS ($3.96) ($5.73) ($5.37) ($7.55) ($7.88) P/E NM NM NM NM NM Thomas J..
LifeSci Capital Analyst forecast on IRON
LifeSci Capital
LifeSci Capital
$85
Buy
44.75%
Upside
Reiterated
08/07/25
Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
TD Cowen
Buy
Reiterated
08/07/25
Disc Medicine (IRON) Receives a Buy from TD Cowen
Raymond James Analyst forecast on IRON
Raymond James
Raymond James
$89
Buy
51.57%
Upside
Reiterated
07/18/25
Raymond James Reaffirms Their Buy Rating on Disc Medicine (IRON)
Scotiabank Analyst forecast on IRON
Scotiabank
Scotiabank
$75
Buy
27.72%
Upside
Reiterated
06/17/25
Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)
BMO Capital Analyst forecast on IRON
BMO Capital
BMO Capital
$120
Buy
104.36%
Upside
Reiterated
06/17/25
BMO Capital Reaffirms Their Buy Rating on Disc Medicine (IRON)
Wells Fargo Analyst forecast on IRON
Wells Fargo
Wells Fargo
$91
Buy
54.97%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Disc Medicine (NASDAQ: IRON)
Jefferies Analyst forecast on IRON
Jefferies
Jefferies
$111
Buy
89.03%
Upside
Reiterated
03/13/25
Disc Medicine's Strategic Advances and Market Potential Drive Positive Analyst Rating
Stifel Nicolaus Analyst forecast on IRON
Stifel Nicolaus
Stifel Nicolaus
$94$92
Buy
56.68%
Upside
Reiterated
03/03/25
Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)
Wedbush
$90
Buy
53.27%
Upside
Initiated
02/27/25
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Disc Medicine (NASDAQ: IRON) and Roche Holding (Other OTC: RHHBY)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on IRON
Cantor Fitzgerald
Cantor Fitzgerald
$132
Buy
124.80%
Upside
Reiterated
08/20/25
Cantor Fitzgerald Sticks to Its Buy Rating for Disc Medicine (IRON)Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $132.00 price target on Disc Medicine (NASDAQ: IRON).
Morgan Stanley Analyst forecast on IRON
Morgan Stanley
Morgan Stanley
$85$90
Buy
53.27%
Upside
Reiterated
08/18/25
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)
H.C. Wainwright Analyst forecast on IRON
H.C. Wainwright
H.C. Wainwright
$118
Buy
100.95%
Upside
Reiterated
08/08/25
H.C. Wainwright Reaffirms Their Buy Rating on Disc Medicine (IRON)
Truist Financial Analyst forecast on IRON
Truist Financial
Truist Financial
Buy
Reiterated
08/08/25
Disc Medicine (IRON) Receives a Buy from Truist Financial
Leerink Partners Analyst forecast on IRON
Leerink Partners
Leerink Partners
$85
Buy
44.75%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Quanterix (NASDAQ: QTRX) and PTC Therapeutics (NASDAQ: PTCT)We look forward to NDA submission for bitopertin in October 2025, as well as DISC-0974’s initial Phase 2 data in MF anemia (likely ASH in December) and additional Phase 1 results in Reason for report: EARNINGS $85.00 52-Week High – Low: $68.73 - $30.82 Shares Outstanding (mil): 35.2 Market Capitalization (mil): $2,006.0 $18.49 Dividend (ann): $0.00 0.0% Dec Yr 2024A 2025E (New) 2025E (Old) 2026E (New) 2026E (Old) Q1 0.0 0.0A -- -- -- Q2 0.0 0.0A -- -- -- Q3 0.0 0.0 -- -- -- Q4 0.0 0.0 -- -- -- FY Rev 0.0 0.0 -- $30.2 -- Q1 ($1.09) ($1.02)A -- -- -- ($1.20) -- -- Q3 ($0.89) ($1.43) -- -- -- ($1.70) -- -- FY EPS ($3.96) ($5.73) ($5.37) ($7.55) ($7.88) P/E NM NM NM NM NM Thomas J..
LifeSci Capital Analyst forecast on IRON
LifeSci Capital
LifeSci Capital
$85
Buy
44.75%
Upside
Reiterated
08/07/25
Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
TD Cowen
Buy
Reiterated
08/07/25
Disc Medicine (IRON) Receives a Buy from TD Cowen
Raymond James Analyst forecast on IRON
Raymond James
Raymond James
$89
Buy
51.57%
Upside
Reiterated
07/18/25
Raymond James Reaffirms Their Buy Rating on Disc Medicine (IRON)
Scotiabank Analyst forecast on IRON
Scotiabank
Scotiabank
$75
Buy
27.72%
Upside
Reiterated
06/17/25
Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)
BMO Capital Analyst forecast on IRON
BMO Capital
BMO Capital
$120
Buy
104.36%
Upside
Reiterated
06/17/25
BMO Capital Reaffirms Their Buy Rating on Disc Medicine (IRON)
Wells Fargo Analyst forecast on IRON
Wells Fargo
Wells Fargo
$91
Buy
54.97%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Disc Medicine (NASDAQ: IRON)
Jefferies Analyst forecast on IRON
Jefferies
Jefferies
$111
Buy
89.03%
Upside
Reiterated
03/13/25
Disc Medicine's Strategic Advances and Market Potential Drive Positive Analyst Rating
Stifel Nicolaus Analyst forecast on IRON
Stifel Nicolaus
Stifel Nicolaus
$94$92
Buy
56.68%
Upside
Reiterated
03/03/25
Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)
Wedbush
$90
Buy
53.27%
Upside
Initiated
02/27/25
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Disc Medicine (NASDAQ: IRON) and Roche Holding (Other OTC: RHHBY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Disc Medicine

1 Month
xxx
Success Rate
13/17 ratings generated profit
76%
Average Return
+9.94%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +9.94% per trade.
3 Months
xxx
Success Rate
15/20 ratings generated profit
75%
Average Return
+20.70%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +20.70% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
16/20 ratings generated profit
80%
Average Return
+12.29%
reiterated a buy rating 15 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +12.29% per trade.
2 Years
xxx
Success Rate
17/20 ratings generated profit
85%
Average Return
+22.68%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.00% of your transactions generating a profit, with an average return of +22.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRON Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
11
16
17
20
12
Buy
2
3
4
7
9
Hold
3
4
3
1
0
Sell
2
2
1
0
0
Strong Sell
0
0
0
0
0
total
18
25
25
28
21
In the current month, IRON has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRON average Analyst price target in the past 3 months is 99.25.
Each month's total comprises the sum of three months' worth of ratings.

IRON Financial Forecast

IRON Earnings Forecast

Next quarter’s earnings estimate for IRON is -$1.48 with a range of -$1.74 to -$1.18. The previous quarter’s EPS was -$1.58. IRON beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.33% of the time in the same period. In the last calendar year IRON has Outperformed its overall industry.
Next quarter’s earnings estimate for IRON is -$1.48 with a range of -$1.74 to -$1.18. The previous quarter’s EPS was -$1.58. IRON beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.33% of the time in the same period. In the last calendar year IRON has Outperformed its overall industry.
No data currently available

IRON Sales Forecast

Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.78% of the time in the same period. In the last calendar year IRON has Preformed in-line its overall industry.
Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.78% of the time in the same period. In the last calendar year IRON has Preformed in-line its overall industry.

IRON Stock Forecast FAQ

What is IRON’s average 12-month price target, according to analysts?
Based on analyst ratings, Disc Medicine, Inc.’s 12-month average price target is 99.25.
    What is IRON’s upside potential, based on the analysts’ average price target?
    Disc Medicine, Inc. has 69.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IRON a Buy, Sell or Hold?
          Disc Medicine, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Disc Medicine, Inc.’s price target?
            The average price target for Disc Medicine, Inc. is 99.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $132.00 ,the lowest forecast is $75.00. The average price target represents 69.02% Increase from the current price of $58.72.
              What do analysts say about Disc Medicine, Inc.?
              Disc Medicine, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IRON?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis